Pfizer Could Year-End Target Hit on 2-to-1 Trial Payoff
Pfizer stock climbs as analysts weigh a pivotal prostate cancer trial. A Guggenheim bull case sees a $36 target by ye...
Indices adjust divisors to reflect corporate actions and maintain continuity. This note covers the main reasons these changes occur.
28,369 articlesPfizer stock climbs as analysts weigh a pivotal prostate cancer trial. A Guggenheim bull case sees a $36 target by ye...
XRP broke out of a tight technical pattern that traders say could lead to a 100% surge toward the $2-$4 zone. The set...
Coinbase launches three new perpetual contracts that track MarketVector AI, Defense, and China indexes, giving trader...
As market volatility persists, a three-fund, monthly-payer strategy aims to deliver around $9,000 annual passive inco...
A Bitcoin-native DeFi project is winding down amid weak demand, underscoring a broader hurdle for BTC yield ecosystem...
Investors wonder about the path ahead for Lucid stock. This guide lays out three scenarios, the key drivers, and conc...
Bitcoin steadies above $60k as traders weigh a delicate recovery against stubborn resistance. The coming days will cl...
Geopolitical risk around the Strait of Hormuz is flaring. This report examines which warships that could dominate Hor...
Cotality unveiled its Broker Listing Exchange (BLX), with Keller Williams and HomeServices of America as the first ad...
Mondelez stock inches toward a golden cross as easing cocoa prices and stronger emerging-market demand rally the snac...
You're weighing two paths: paying down a rental mortgage or buying additional rental doors. This guide breaks down th...
The U.S. government has imposed export controls on Anthropic’s Fable and Mythos, effectively creating a licensing reg...